Get the Stockscreener App
3.57
5.05%
-0.19
Galectin Therapeutics Inc stock is traded at $3.57, with a volume of 185.88K.
It is down -5.05% in the last 24 hours and up +27.50% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$3.76
Open:
$3.79
24h Volume:
185.88K
Relative Volume:
0.30
Market Cap:
$225.95M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-4.8904
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
-13.98%
1M Performance:
+27.50%
6M Performance:
+153.19%
1Y Performance:
+63.01%
1-Day Range:
$3.56
$3.8388
1-Week Range:
$3.55
$4.25
52-Week Range:
$0.726
$4.41
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
3.57 | 237.98M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Signal strength of Galectin Therapeutics Inc. stock in tech scannersJuly 2025 Summary & Scalable Portfolio Growth Methods - Newser
Galectin Therapeutics' (GALT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Announces Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Is Galectin Therapeutics Inc. a turnaround story2025 Biggest Moves & Community Verified Trade Alerts - thegnnews.com
What recovery options are there for Galectin Therapeutics Inc.2025 Trading Volume Trends & Expert Curated Trade Setup Alerts - Newser
Does Galectin Therapeutics Inc. qualify in momentum factor screeningWeekly Market Report & Safe Entry Point Identification - Newser
Does Galectin Therapeutics Inc. show high probability of reboundEarnings Risk Report & Consistent Growth Equity Picks - Newser
Backtesting results for Galectin Therapeutics Inc. trading strategiesWeekly Loss Report & Fast Moving Trade Plans - Newser
Top Risks to Consider Before Buying Galectin Therapeutics Inc. StockJuly 2025 Momentum & AI Enhanced Execution Alerts - Newser
Earnings visualization tools for Galectin Therapeutics Inc.Weekly Trend Report & Fast Entry High Yield Tips - Newser
Quantitative breakdown of Galectin Therapeutics Inc. recent moveBull Run & Growth-Oriented Investment Plans - Newser
Galectin Therapeutics Inc. stock retracement – recovery analysisEarnings Recap Summary & Consistent Income Trade Ideas - Newser
What makes Galectin Therapeutics Inc. stock price move sharply2025 Trading Volume Trends & Precise Trade Entry Recommendations - Newser
Comparing Galectin Therapeutics Inc. in custom built stock radarsWeekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Combining price and volume data for Galectin Therapeutics Inc.Trade Volume Report & Capital Protection Trade Alerts - Newser
Predicting Galectin Therapeutics Inc. trend using moving averagesJuly 2025 PostEarnings & Short-Term Swing Trade Alerts - Newser
why galectin therapeutics inc. stock attracts strong analyst attentionQuarterly Trade Summary & Community Consensus Trade Alerts - Newser
Galectin Therapeutics Reports Reduced Losses in Q2 2025 - MSN
Can Galectin Therapeutics Inc. Regain Lost Ground This QuarterMarket Trend Report & Free Real-Time Market Sentiment Alerts - newsyoung.net
Is Now The Right Time To Buy Galectin Therapeutics Inc (NASDAQ: GALT) Stock? - stocksregister.com
Galectin Therapeutics’ (GALT) Buy Rating Reaffirmed at HC Wainwright - Defense World
Galectin Beats Q2 Loss Estimates - Nasdaq
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update - Yahoo Finance
Strategies to average down on Galectin Therapeutics Inc.Market Risk Report & Verified Short-Term Plans - Newser
Will Galectin Therapeutics Inc. stock recover after recent dropIPO Watch & Weekly Top Stock Performers List - Newser
What data driven models say about Galectin Therapeutics Inc.’s futureProfit Target & Low Risk Entry Point Guides - Newser
How institutional ownership impacts Galectin Therapeutics Inc. stockEarnings Beat & Stepwise Trade Signal Implementation - Newser
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Galectin Therapeutics Inc. stock trend outlook and recovery pathLow Drawdown Picks with Weekly Updates - Newser
What the charts say about Galectin Therapeutics Inc. todayRisk/Reward Optimization Entry Point Analysis - Newser
How Galectin Therapeutics Inc. stock performs during market volatilityDaily Swing Candidate Analysis with Chart Patterns - Newser
Galectin Therapeutics (GALT) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Galectin GALT 2025Q2 Earnings Preview Upside Potential on Immunotherapy Advancements - AInvest
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Galectin Therapeutics Inc Stock (GALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FREEMAN KEVIN D | Director |
Jul 17 '25 |
Buy |
2.90 |
5,000 |
14,495 |
49,769 |
| CZIRR JAMES C | 10% Owner |
Jun 06 '25 |
Option Exercise |
2.16 |
323,125 |
699,344 |
1,045,541 |
| Shlevin Harold H. | Director |
Dec 30 '24 |
Buy |
1.16 |
6,500 |
7,540 |
15,206 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
40,000 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Sale |
0.88 |
13,654 |
12,044 |
26,346 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Option Exercise |
0.00 |
56,000 |
0 |
953,012 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Sale |
0.89 |
56,000 |
49,610 |
897,012 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
47,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Sale |
0.89 |
40,000 |
35,492 |
7,614 |
| Zordani Richard A. Jr. | Director |
Dec 24 '24 |
Buy |
0.82 |
10,000 |
8,164 |
42,083 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):